BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 21322567)

  • 1. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
    Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
    J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
    Gambacorti-Passerini C; Gasser M; Ahmed S; Assouline S; Scapozza L
    Leukemia; 2005 Jul; 19(7):1267-9. PubMed ID: 15858616
    [No Abstract]   [Full Text] [Related]  

  • 4. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
    J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
    Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
    J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
    Mol CD; Fabbro D; Hosfield DJ
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors.
    Aronov AM; Bemis GW
    Proteins; 2004 Oct; 57(1):36-50. PubMed ID: 15326593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.